|
[1]
|
Behin A, Psimaras D, Hoang K, et al. Neuropathies in the context of malignancies[J]. Curr Opin Neurol, 2008, 21(5):534-539. doi: 10.1097/WCO.0b013e32830f226d
|
|
[2]
|
Raffaghello L, Fuhlhuber V, Bianchi G, et al. Role of BAFF in opsoclonusmyoclonus syndrome, a bridge between cancer and autoimmunity[J]. J Leukoc Biol, 2013, 94(1):183-191. doi: 10.1189/jlb.0213106
|
|
[3]
|
Pranzatelli MR, Tate ED, McGee NR, et al. CCR7 signaling in pediatric opsoclonus-myoclonus:upregulated serum CCL21 expression is steroid-responsive[J]. Cytokine, 2013, 64(1):331-336. http://med.wanfangdata.com.cn/Paper/Detail/PeriodicalPaper_PM23764550
|
|
[4]
|
Pike M. Opsoclonus-myoclonus syndrome[J]. Handb Clin Neurol, 2013, 112:1209-1211. doi: 10.1016/B978-0-444-52910-7.00042-8
|
|
[5]
|
Corapcioglu F, Mutlu H, Kara B, et al. Response to rituximab and prednisolone for opsoclonus-myoclonus-ataxis syndrome in a child with ganglioneuroblastoma[J]. Pediatr Hematol Oncol, 2008, 25(8):756-761. doi: 10.1080/08880010802341690
|
|
[6]
|
Pranzatelli MR, Tate ED, Verhulst SJ, et al. Pediatric dosing of rituximab revisited:serum concentrations in opsoclonus-myoclonus syndrome[J]. Pediatr Hematol Oncol, 2010, 32(5):167-172 doi: 10.1097/MPH.0b013e3181cf0726
|
|
[7]
|
Pranzatelli MR, Tate ED, Swan JA. B cell depletion therapy for newonset opsoclonus-myoclonus[J]. Mov Disord, 2010, 25(2):238-242. doi: 10.1002/mds.22941
|
|
[8]
|
Oguma M, Morimoto A, Takada A, et al. Another promising treatment option for neuroblastoma-associated opsoclonus-myoclonus syndrome by downloaded by oral high-dose dexamethasone pulse:lymphocyte markers as disease activity[J]. Brain Dev, 2012, 34(3):251-254. doi: 10.1016/j.braindev.2011.04.005
|
|
[9]
|
van Vuurden DG, Plotz FB, De Jong M, et al. Therapeutic total plasma exchange in a child with neuroblastoma-related anti-Hu syndrome[J]. Pediatr Nephrol, 2005, 20(11):1655. doi: 10.1007/s00467-005-2004-8
|
|
[10]
|
Matasumoto H, Ugawa Y. Paraneoplastic opsoclonus-myoclonus syndrome-a review[J]. Brain Nerve, 2010, 62(4):365-369. http://d.old.wanfangdata.com.cn/NSTLQK/NSTL_QKJJ0216487871/
|
|
[11]
|
Klein A, Schmitt B, Boltshauser E. Long-term outcome of ten children with opsoclonus-myoclonus syndrome[J]. Eur J Pediatr, 2007, 166(4):359-363. doi: 10.1007/s00431-006-0247-4
|
|
[12]
|
Rudnick E, Khakoo Y, Antunes NL, et al. Opsoclonus-myoclonus-ataxia syndrome in neuroblastoma:CIinic outcome and antineuronal antibodies-a report from the Children's cancer group study[J]. Med Pediatr Oncol, 200l, 36(6):612-622. doi: 10.1002/mpo.1138
|
|
[13]
|
陈丽.神经系统副肿瘤综合征的临床表现[J].中国实验诊断学, 2014, (8):1377-1380. http://d.old.wanfangdata.com.cn/Periodical/zgsyzdx201408069
|
|
[14]
|
朱红强, 周茜, 陈敬银, 等.神经系统副肿瘤综合征[J].中国实用神经疾病杂志, 2013, 16(16):87-89. doi: 10.3969/j.issn.1673-5110.2013.16.063
|
|
[15]
|
Catsman-Berrevoets CE, Aarsen FK, van Hemsbergen ML, et al. Improvement of neurological status and quality of life in children with opsoclonus myoclonus syndrome at long-term follow-up[J]. Pediatr Blood Cancer, 2009, 53(6):1048-1053. doi: 10.1002/pbc.22226
|
|
[16]
|
王湘, 白春梅.神经系统副肿瘤综合征的研究进展[J].癌症进展, 2011, 9(1):58-62. doi: 10.3969/j.issn.1672-1535.2011.01.011
|
|
[17]
|
金仙梅, 张语桐, 王立哲, 等.神经母细胞瘤副肿瘤综合征临床分析[J].中国小儿血液与肿瘤杂志, 2018, 23(5):260-263. doi: 10.3969/j.issn.1673-5323.2018.05.008
|
点击查看大图
下载:
